Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Cash & Equivalents (2020 - 2025)

Celularity (CELU) has disclosed Cash & Equivalents for 6 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 736.72% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 736.72%, while the annual FY2025 figure was $6.2 million, 736.72% up from the prior year.
  • Cash & Equivalents hit $6.2 million in Q4 2025 for Celularity, up from $120000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $72.7 million in Q3 2021 and bottomed at $211.0 in Q2 2021.
  • Average Cash & Equivalents over 5 years is $13.8 million, with a median of $1.4 million recorded in 2024.
  • Year-over-year, Cash & Equivalents plummeted 99.97% in 2021 and then surged 18007482.94% in 2022.
  • Celularity's Cash & Equivalents stood at $37.2 million in 2021, then crashed by 62.5% to $14.0 million in 2022, then crashed by 98.37% to $227000.0 in 2023, then soared by 225.11% to $738000.0 in 2024, then surged by 736.72% to $6.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $6.2 million, $120000.0, and $863000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.